Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.3 USD | +3.29% | -1.35% | -56.86% |
Mar. 26 | GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Feb. 01 | GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Capitalization 1 | 5.462 | 35.83 | 93.05 | 28.84 | 10.56 | 4.556 |
Enterprise Value (EV) 1 | 5.462 | 35.83 | 93.05 | 28.84 | 10.56 | 4.556 |
P/E ratio | -0.12 x | -1.12 x | -1.48 x | -1.34 x | -1.36 x | -0.31 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | - | - | -5,960,929 x | - | - | - |
FCF Yield | - | - | -0% | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 132 | 166 | 1,017 | 1,085 | 1,381 | 1,381 |
Reference price 2 | 41.31 | 216.2 | 91.50 | 26.57 | 7.650 | 3.300 |
Announcement Date | 3/27/20 | 4/16/21 | 3/28/22 | 3/30/23 | 3/26/24 | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - |
EBIT 1 | - | -6.764 | -57.52 | -21.26 | -13.58 | -17.41 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -28.3 | -58.01 | -20.88 | -7.597 | -17.41 |
Net income 1 | -38.65 | -28.3 | -58.01 | -20.88 | -7.597 | -17.41 |
Net margin | - | - | - | - | - | - |
EPS 2 | -341.7 | -193.5 | -61.80 | -19.80 | -5.640 | -10.80 |
Free Cash Flow | - | - | -15.61 | - | - | - |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 3/27/20 | 4/16/21 | 3/28/22 | 3/30/23 | 3/26/24 | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -5.954 | -18.18 | -5.442 | -3.014 | -7.023 | -5.778 | -3.665 | -3.621 | -3.122 | -3.168 | -3.882 | -4.208 | -4.519 | -4.805 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -5.453 | -18.02 | -5.44 | -2.979 | -6.881 | -5.584 | -0.227 | -1.992 | -2.416 | -2.962 | -3.882 | -4.208 | -4.519 | -4.805 |
Net income 1 | -5.453 | -18.02 | -5.44 | -2.979 | -6.881 | -5.584 | -0.227 | -1.992 | -2.416 | -2.962 | -3.882 | -4.208 | -4.519 | -4.805 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -5.100 | -15.60 | -5.100 | -3.000 | -6.600 | -5.400 | -0.3000 | -1.500 | -1.800 | -5.520 | -2.700 | -2.700 | -2.700 | -3.000 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/10/21 | 3/28/22 | 5/16/22 | 8/15/22 | 10/31/22 | 3/30/23 | 5/15/23 | 8/7/23 | 11/1/23 | 3/26/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow | - | - | -15.6 | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - |
Capex | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 3/27/20 | 4/16/21 | 3/28/22 | 3/30/23 | 3/26/24 | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-56.86% | 4.56M | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B |
- Stock Market
- Equities
- GTBP Stock
- Financials GT Biopharma, Inc.